Skip to main content

Table 3 Toxicities in stage II patients who received h-R3/RT or CDDP/RT (N = 26)

From: A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

Toxicities (RTOG Grade) h-R3/RT (N = 13) [n (%)] CDDP/RT (N = 13) [n (%)] P Value*
WBC    0.711
 (1&2) 10 (76.9%) 6 (46.2%)  
 (3&4) 0 (0.0%) 3 (23.1%)  
PLT    0.380
 (1&2) 6 (46.2%) 6 (46.2%)  
 (3&4) 0 (0.00%) 1 (7.7%)  
HB    0.083
 (1&2) 8 (61.5%) 5 (61.5%)  
 (3&4) 0 (0.0%) 0 (0.0%)  
ALT    0.655
 (1&2) 2 (15.4%) 3 (23.1%)  
 (3&4) 0 (0.0%) 0 (0.0%)  
AST    0.157
 (1&2) 2 (15.4%) 0 (0.0%)  
 (3&4) 0 (0.0%) 0 (0.0%)  
GGT    1.000
 (1&2) 1 (7.7%) 1 (7.7%)  
 (3&4) 0 (0.0%) 0 (0.0%)  
Dermatitis    0.414
 (1&2) 8 (61.5%) 11 (84.6%)  
 (3&4) 0 (0.0%) 0 (0.0%)  
Rash    0.655
 (1&2) 3 (23.1%) 2 (15.4%)  
 (3&4) 0 (0.0%) 0 (0.0%)  
Mucositis    0.093
 (1&2) 5 (38.5%) 8 (61.5%)  
 (3&4) 7 (53.8%) 5 (38.5%)  
Taste change    1.000
 yes 13 (100%) 13 (100%)  
 no 0 (0.0%) 0 (0.0%)  
Vomit    0.046*
 only nausea 6 (46.2%) 3 (23.1%)  
 Nausea and vomit 2 (15.4%) 10 (76.9%)  
Weight loss    0.305
 (1&2) 8 (61.6%) 7 (53.8%)  
 (3&4) 3 (23.1%) 5 (38.5%)  
  1. Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy
  2. *All p values were obtained using the paired rank sum test